Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?

Cancer

Volumn 85, Issue 11, 1999, Pages 2450-2454

  Kamura, Toshiharu ^a   Yahata, Hideaki ^a   Amada, Satoshi ^a   Ogawa, Shinji ^a   Sonoda, Takanori ^a   Kobayashi, Hiroaki ^a   Mitsumoto, Masamune ^a   Kohno, Kimitoshi ^b   Kuwano, Michihiko ^a   Nakano, Hitoo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cisplatin resistance; Immunostaining; Ovarian carcinoma; Prognosis; Y box binding protein 1

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA BINDING PROTEIN; EPIRUBICIN; GLYCOPROTEIN P;

ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CCAAT-ENHANCER-BINDING PROTEINS; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NFI TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROGNOSIS; TRANSCRIPTION FACTORS; Y-BOX-BINDING PROTEIN 1;

EID: 0033152542     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U     Document Type: Article

References (24)

1. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55-60.
2. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
3. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070-4.
4. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer lines to cisplatin. Cancer Res 1991;51:3237-42.
5. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988;27:4730-4.
6. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988;48:5713-6.
7. Andrews PA, Velury S, Mann SC, Howell SB. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48(1):68-73.
8. Nakagawa M, Nomura Y, Kohno K, Ono M, Mizoguchi H, Ogata J, et al. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J Urol 1993;150:1970-3.
9. Kotoh S, Naito S, Yokomizo A, Kumazawa J, Asakuno K, Kohno K, et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994; 54(12):3248-52.
10. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-6.
11. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56: 4224-8.
12. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol 1995; 14:134-42.
13. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988;85:7322-6.
14. Yan C, Tamm I. Molecular cloning and characterization of interferon alpha/beta response element binding factors of the murine (2′-5′)oligoadenylate synthetase ME-12 gene [published erratum appears in Proc Natl Acad Sci USA 1991; 88(6):2612]. Proc Natl Acad Sci USA 1991;88:144-8.
15. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3(4):447-50.
16. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano K. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem 1990;265:19690-6.
17. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-4.
18. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
19. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 1993;4:147-57.
20. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. In press.
21. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993;268:20116-25.
22. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996;56:4124-9.
23. Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52:313-9.
24. Tanner B, Hengstler JG, Dietrich B, Henrich M, Steinberg P, Weikel W, et al. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 1997;65: 54-62.